Amgen To Present Robust Data Exploring The Impact Of Treatment With Repatha ® (evolocumab) Across Patient Subgroups And High-Risk Populations At ESC Congress 2018

New Research Evaluates the Benefit of LDL-C Lowering With Repatha Across Gender and Age Data Assesses the Financial Burden for Patients in Europe With Atherosclerotic Cardiovascular Disease THOUSAND OAKS, Calif., Aug. 21, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the upcoming presentation of new Repatha® (evolocumab) analyses, including a late-breaking study evaluating the efficacy of Repatha in patients with metabolic syndrome and established cardiovascular disease at the ESC Congress 2018, organized by the European Society of Cardiology, in Munich, Aug. 25-29. Six abstracts, including two analyses from the Repatha cardiovascular outcomes study (FOURIER), will be ...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news